You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PNAS this week: induced "BRCAness" phenotype in non-small cell lung cancer, chemoproteomic profiling approach, and more.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
One of the largest repositories of molecular brain cancer data in the world, the enhanced REMBRANDT is more comprehensive than an earlier NCI-hosted version.
The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.
Considering the widespread use of the cell line, these findings could have significant implications for the research community.
Biocept hopes data from the study will support the clinical utility of its liquid biopsy test to detect drug resistance mutations in NSCLC.
Researchers from EBI, Georgetown, and others are mapping protein annotations to the human reference genome to it more easily accessible.
The partners have jointly developed a research agenda including immune-therapy and NGS with the goal of creating an NCI-recognized oncology consortium.
The Caris Centers of Excellence for Precision Medicine Network will establish tumor profiling standards and provide access to Caris' database of patient outcomes.
The deal opens the door for Amarantus to license as many as six patents to help diagnose patients at risk of developing Alzheimer's disease.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.